Immix Biopharma (IMMX) Share-based Compensation (2021 - 2026)

Immix Biopharma has disclosed Share-based Compensation across 6 years of filings, most recently posting $508065.0 for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $508065.0, up 16.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 17.38% YoY), and the FY2025 annual result was $2.4 million, down 19.16% from the prior year.
• Share-based Compensation came in at $508065.0 for Q1 2026 at Immix Biopharma, down from $570796.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.1 million in Q4 2023 to a low of $65074.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $329919.0 (2023), against an average of $380630.9.
• Across the five-year window, Share-based Compensation surged 1432.23% in 2022 and tumbled 74.46% in 2025, its largest moves.
• Immix Biopharma's Share-based Compensation stood at $82771.0 in 2022, then jumped by 1169.54% to $1.1 million in 2023, then sank by 32.85% to $705653.0 in 2024, then fell by 19.11% to $570796.0 in 2025, then fell by 10.99% to $508065.0 in 2026.
• The last three Share-based Compensation figures came in at $508065.0 (Q1 2026), $570796.0 (Q4 2025), and $402971.0 (Q3 2025), per Business Quant data.